Form 4: CRISPR CFO Sells 10,000 Shares Under 10b5-1 Plan

CRISPR Therapeutics AG's Chief Financial Officer, Raju Prasad, reported the sale of 10,000 common shares for approximately $559,584.80 through a pre-arranged 10b5-1 trading plan.

Summary

• Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG, reported the sale of 10,000 common shares.
• The sales occurred on December 22, 2025, and were executed under a Rule 10b5-1 trading plan adopted on August 18, 2025.
• The shares were sold in three separate transactions at weighted average prices of $55.1022, $56.3345, and $56.8858.
• The total value of the shares sold is approximately $559,584.80.
• Following these transactions, Mr. Prasad directly beneficially owns 6,767 common shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the fact that it's under a 10b5-1 plan mitigates concerns, indicating a pre-planned, non-discretionary transaction for personal financial management rather than a reaction to new company-specific negative news.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and automated divestment rather than a discretionary sale based on new, non-public information.

Negatives

• The Chief Financial Officer sold a significant number of shares (10,000), which could be interpreted by some investors as a lack of confidence, despite being part of a 10b5-1 plan.
• The total value of shares sold is approximately $559,584.80.

Future Outlook

The filing reports sales that were executed on December 22, 2025, pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025. This indicates that the divestment by the CFO was pre-scheduled and not a discretionary sale based on immediate market conditions.

Industry Context

Insider selling, even under a 10b5-1 plan, is a common occurrence in the biotechnology sector, particularly for executives who receive significant equity compensation. It typically reflects personal financial planning rather than a specific negative outlook on the company, especially when pre-scheduled.

Related Party Transactions

• The reported sales of common shares by Raju Prasad, the Chief Financial Officer, constitute a related party transaction as it involves a key executive of the company.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to short-term price volatility, although the 10b5-1 plan mitigates this concern.

Key Dates

Recommendation

The insider selling by the CFO, while notable, was conducted under a pre-arranged 10b5-1 trading plan. This suggests a systematic approach to managing personal equity holdings rather than a reaction to new material information. Therefore, this specific filing does not provide a strong basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as investors should look to broader company fundamentals and market conditions for investment decisions.

Keywords

CRISPR Therapeutics, CRSP, Insider Selling, Form 4, Raju Prasad, CFO, Stock Sale, 10b5-1 Plan, Biotechnology, Gene Editing